Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Hochhauser

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Current Opinion in Pharmacology|April 17, 2012
Small molecule drugs - optimizing DNA damaging agent-based therapeuticsJohn A Hartley, Daniel Hochhauser
The Lancet. Oncology|July 3, 2004
Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrumAndrew Burroughs, Daniel Hochhauser, Tim Meyer
Cancer Research|January 27, 2011
EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatmentGianmaria Liccardi, John A Hartley, Daniel Hochhauser
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2014
Importance of EGFR/ERCC1 interaction following radiation-induced DNA damageGianmaria Liccardi, John A Hartley, Daniel Hochhauser
Critical Reviews in Oncology/Hematology|February 6, 2022
The role of PARP inhibitors in gastrointestinal cancersDaire Hanna, Neha Chopra, Daniel Hochhauser, et al.
BMC Medical Informatics and Decision Making|October 28, 2017
Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English settingAris Angelis, Gilberto Montibeller, Daniel Hochhauser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839)Benjamin Friedmann, Martyn Caplin, John A Hartley, et al.
Journal of Cell Science|June 25, 2017
Stress-specific p38 MAPK activation is sufficient to drive EGFR endocytosis but not its nuclear translocationAlejandra Tomas, Sylwia Jones, Simon O Vaughan, et al.
Cell Death and Differentiation|May 6, 2017
mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanismAikaterini Lampada, James O'Prey, Gyorgy Szabadkai, et al.
Molecular Cancer Therapeutics|November 6, 2009
Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agentsJulien J M Boone, Jaishree Bhosle, Mike J Tilby, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Current Opinion in Pharmacology|April 17, 2012
Small molecule drugs - optimizing DNA damaging agent-based therapeuticsJohn A Hartley, Daniel Hochhauser
The Lancet. Oncology|July 3, 2004
Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrumAndrew Burroughs, Daniel Hochhauser, Tim Meyer
Cancer Research|January 27, 2011
EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatmentGianmaria Liccardi, John A Hartley, Daniel Hochhauser
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2014
Importance of EGFR/ERCC1 interaction following radiation-induced DNA damageGianmaria Liccardi, John A Hartley, Daniel Hochhauser
Critical Reviews in Oncology/Hematology|February 6, 2022
The role of PARP inhibitors in gastrointestinal cancersDaire Hanna, Neha Chopra, Daniel Hochhauser, et al.
BMC Medical Informatics and Decision Making|October 28, 2017
Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English settingAris Angelis, Gilberto Montibeller, Daniel Hochhauser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839)Benjamin Friedmann, Martyn Caplin, John A Hartley, et al.
Journal of Cell Science|June 25, 2017
Stress-specific p38 MAPK activation is sufficient to drive EGFR endocytosis but not its nuclear translocationAlejandra Tomas, Sylwia Jones, Simon O Vaughan, et al.
Cell Death and Differentiation|May 6, 2017
mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanismAikaterini Lampada, James O'Prey, Gyorgy Szabadkai, et al.
Molecular Cancer Therapeutics|November 6, 2009
Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agentsJulien J M Boone, Jaishree Bhosle, Mike J Tilby, et al.
Pageof 7